Sun Pharmaceutical Industries tumbles after Q4FY16 results

Sun Pharmaceutical Industries (SPIL) has declared its quarterly results on Monday. The company’s revenue has increased by 23.99 per cent to Rs 7634 crore in Q4FY16 as compared to same period in previous financial year. Its EBITDA stands at Rs 2520 crore in Q4FY16 with margin of 33.01 per cent. SPIL’s net profit stands at Rs 1714 crore in Q4FY16 against net profit of Rs 888 crore in Q4FY15.

On yearly front, SPIL’s top line has increased by 3.05 per cent to Rs 28270 crore in FY16 as compared to previous financial year. The company’s EBITDA also has risen by 5.18 per cent to Rs 8482 crore in FY16 on a yearly basis. Its EBITDA margin has expanded by 61 basis points to 30 per cent in FY16 on a yearly basis. SPIL’s EBITDA margin has expanded by 61 basis points to 30 per cent in FY16 as compared to previous fiscal year. The company’s bottom line has increased by 3.86 per cent to Rs 4716 crore in FY16 on a yearly basis. Its net profit margin has expanded by 13 basis points to 16.68 per cent in FY16 as compared to previous fiscal year. SPIL’s 7 new products were commercialised in Q4FY16 and 29 new products were launched during FY16 in the Indian market.

The share price of SPIL has declined by 5.79 per cent on bourses in early trades; and is trading at Rs 766.45 on an intraday basis.

SPIL provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. The company’s global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. SPIL’s API business footprint is strengthened through 14 world class API manufacturing facilities across the globe.